Effect of Burn Size on Cytomegalovirus Reactivation and Correlates of T Cell Immune Function in Burned Patients
A Prospective Longitudinal Study of the Effect of Burn Size on Cytomegalovirus Reactivation and Correlates of T Cell Immune Function in Patients Sustaining Significant Burn Injury
1 other identifier
observational
60
1 country
1
Brief Summary
The purpose of this study is to evaluate the effect of burn injury on the human immune system with a focus on cytomegalovirus (CMV) reactivation and the immunologic correlates of latent viral reactivation. Subjects will be patients admitted to the North Carolina Jaycee Burn Center with burn injury. Blood samples will be collected over time and will be evaluated for CMV reactivation and immune cell phenotype.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for all trials
Started Mar 2007
Longer than P75 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
March 1, 2007
CompletedFirst Submitted
Initial submission to the registry
April 26, 2007
CompletedFirst Posted
Study publicly available on registry
April 30, 2007
CompletedPrimary Completion
Last participant's last visit for primary outcome
March 1, 2011
CompletedStudy Completion
Last participant's last visit for all outcomes
March 1, 2011
CompletedJanuary 17, 2013
January 1, 2013
4 years
April 26, 2007
January 16, 2013
Conditions
Outcome Measures
Primary Outcomes (1)
CMV IgG and viral load PCR
Weekly until viremia resolved (negative viral load by PCR)
Eligibility Criteria
Patients admitted to the North Carolina Jaycee Burn Center within 72 hours of burn injury with at least a 10% Total Body Surface (TBSA)burn and expected length of stay at least two weeks.
You may qualify if:
- Burn injury,
- Positive CMV IgG level confirmative of previous CMV infection and latency.
You may not qualify if:
- Immunocompromising conditions including HIV/AIDS,
- End-stage renal disease,
- End-stage liver disease,
- Pregnancy,
- Rheumatologic or collagen-vascular disease requiring chronic use of steroids,
- Chronic use of immunosuppressive agents,
- Recent chemotherapy, and
- History of solid organ or allogeneic stem cell transplant.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
North Carolina Jaycee Burn Center, UNC Hospitals
Chapel Hill, North Carolina, 27514, United States
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Bruce Cairns, MD
University of North Carolina, Chapel Hill
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Medical Director, NC Jaycee Burn Center
Study Record Dates
First Submitted
April 26, 2007
First Posted
April 30, 2007
Study Start
March 1, 2007
Primary Completion
March 1, 2011
Study Completion
March 1, 2011
Last Updated
January 17, 2013
Record last verified: 2013-01